Please login to the form below
cell and gene therapy
This page shows the latest cell and gene therapy news and features for those working in and with pharma, biotech and healthcare.
GSK reveals plans for £400m R&D facility expansion in England
The expansion would build on the existing life sciences and biotech presence in Stevenage, including the Cell and Gene Therapy Catapult and SBC which are already on site. ... Our goal is for Stevenage to emerge as a top destination for medical and
Latest news
-
Ashfield launches ‘end-to-end’ cell and gene therapy commercialisation network
UDG Healthcare company Ashfield has launched a new network offering an end-to-end approach for the commercialisation of cell and gene therapies. . ... Health. “EmerGENE is no different, and with over 1, 200 cell and gene therapy clinical trials
-
FDA lifts clinical hold on bluebird bio’s LentiGlobin studies
The US Food and Drug Administration (FDA) has lifted the clinical holds on numerous studies evaluating its gene therapy LentiGlobin for sickle cell disease (SCD) and beta-thalassemia. ... bluebird bio also reported in March that it is ‘very unlikely’
-
eureKARE to use $60m financing to bolster next-generation European biotech companies
New company is focused on financing biotech companies and new ventures in Europe working on the microbiome and synthetic biology. ... Meanwhile, synthetic biology – which comprises gene and cell therapy as well as industrial applications like data
-
Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy
Project will aim to discover and develop a gene therapy for sickle cell disease. ... Swiss pharma company Novartis has entered into an agreement with the Bill &Melinda Gates Foundation for the discovery and development of an ‘accessible’ gene therapy
-
Pfizer's basic instincts
I’m much more interested in the meat of competitive strategies and capabilities. ... Along with other investments, such as in cell and gene therapy, it tells us that Pfizer sees its future success as being even more science-led and innovative than it
Ashfield launches ‘end-to-end’ cell and gene therapy commercialisation network
FDA lifts clinical hold on bluebird bio’s LentiGlobin studies
eureKARE to use $60m financing to bolster next-generation European biotech companies
Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy
Pfizer's basic instincts
More from news
Approximately 40 fully matching, plus 50 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
A crucial challenge faced by cell and gene therapy developers is the necessity to balance clinical considerations with logistical ones such as manufacturing. ... That’s why developers have started exploring other techniques, for example using a
-
Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world
The importance of thinking differently, embracing risk, challenging conventional norms and trying new approaches. ... EBCs also demonstrate positive data and are bringing novel therapies to market in complex areas of medicine, including gene therapy, CAR
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Often lumped together as terms, the key difference between cell therapy and gene therapy is that the former utilises cells from a donor or the patient themselves to treat a disease ... The cell therapy, gene therapy and tissue engineering sector raised $2
-
Gut instincts lead Takeda to GI pipeline success
Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy. ... Takeda’s strategy is to develop GI products that address the highest unmet needs, which includes projects across
-
Delivering the promise of regenerative medicine
The Cell and Gene Therapy Catapult is also continuing to work to bridge the gap between ‘translational’ research and commercialisation. ... to cell and tissue requirements.
Keeping up with the developing regulatory requirements for gene and cell therapies
Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Gut instincts lead Takeda to GI pipeline success
Delivering the promise of regenerative medicine
More from intelligence
Approximately 2 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Health comms agency emotive hires new cell and gene therapy leader
Dr Germano Ferrari. His most recent role was as a programme manager at the UK’s Cell and Gene Therapy Catapult where he helped develop commercialisation pathways for several pre-clinical ... Dr Ferrari said “We have now reached a turning point where
-
Weekly industry appointments
GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”
-
Orchard Therapeutics appoints Mark Rothera as CEO
He said: “Now is an exciting time to be joining Orchard as the cell and gene therapy field is advancing successfully. ... The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and
-
Avita Medical appoints CEO
chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and Genetic Therapy Inc. Lou Panaccio, chairman of Avita, said: “Mike’s expertise across the value chain in cell
-
apceth Biopharma appoints Dusan Kosijer as CFO
He said: “I am excited and honoured to be able to contribute to the company that operates successfully for almost 10 years in the fast-moving field of cell and gene ... successful track record as one of the leading CDMOs for complex cell and gene
Health comms agency emotive hires new cell and gene therapy leader
Weekly industry appointments
Orchard Therapeutics appoints Mark Rothera as CEO
apceth Biopharma appoints Dusan Kosijer as CFO
More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
CRYOPORT APPOINTS MIND+MATTER AS PART OF A GLOBAL BRAND DEVELOPMENT TENDER
Cryoport Inc is the leading global provider of temperature-controlled supply chain solutions and products to the life sciences industry. ... They are the third largest healthcare speciality logistics provider in the world and provide their customers with
-
Windrose Consulting Group
He’s delivered hundreds of engagements spanning over 30 markets in North America, Europe, Asia, and Latin America, with a keen focus in oncology and cell/gene therapy. ... Prior to that she spent 6 years at Simon-Kucher &Partners and ZS.
-
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’. ... outcomes. This is truly unprecedented and more involved than previous solutions to the challenges facing a registry. Early
-
Spotlight interview: 15 minutes on medical and scientific writing
A number of current therapeutic approaches – such as gene editing, gene therapy, and stem-cell therapy – were not in existence when many healthcare professionals (HCPs) underwent their training, so there is ... We have correspondingly invested in
-
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era
the cost curve to accommodate new and expensive cell and gene therapies. In addition to this, insurance plans demand lower co-pays for hospital costs i.e. ... can. Potential methods of payment proposed for expensive cell and gene therapies include:.
Windrose Consulting Group
More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital project manager
-
Competitive
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm
- GSK reveals plans for £400m R&D facility expansion in England
- EU approves bluebird bio’s CALD gene therapy Skysona
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- Using Technology-Enabled Human Interactions to Transform the Home into a Site of Care
- Langland promotes Jake Davis to managing partner
- J&J, distributors reach $26bn settlement to address the opioid crisis in the US
- Novartis sees demand returning to pre-COVID-19 levels in Q2 results
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med
- British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura
- Summer Fridays are back at Lucid Group
- Mark Caulfield departs from Genomics England to take on CEO role at Barts Life Sciences
- Ogilvy Health appoints Rebecca Carter to newly created head of social media role
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
